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ABSTRACT 
 
DAGHFAL, JOANNE, N., Masters of Science: June : [2017], Public Health 
Title: Prevalence of Healthcare Associated Infections in Adults Recipients of Autologous 
Hematopoietic Stem Cell Transplantation in Qatar 
Supervisor ofThesis: Dr.Manar Elhassan. 
Objective 
To analyze the prevalence and characteristics of Healthcare Associated Infections (HAI) in 
patients with hematologic malignancies who underwent Autologous Hematopoietic Stem Cell 
Transplantation (AHSCT) at the National Center for Cancer Care and Research (NCCCR) newly 
opened transplant unit in Qatar between October 2015 and October 2016 with global comparison 
of the bloodstream Infection (BSI) prevalence, one of the most prevalent complications after stem 
cell transplant.  
Methods  
The Center of Disease Control (CDC) definitions for laboratory-confirmed bloodstream infection 
(BSI), modified criteria for pneumonia and hospital-acquired infections were used. Statistical 
analysis was done using STATA version14. The entire healthcare associated infections (HAI) and 
other variables were described using means, proportions and 95% confidence intervals. Meta-
Analysis of Observational Studies in Epidemiology guidelines was applied in conducting the 
meta-analysis. The systematic search in English was done in PubMed from 1970 (date of stem 
cell transplant kick off) to 2016. Inclusion was restricted to human hematology studies that 
included AHSCT. Statistical calculations allowing an accurate estimation of the prevalence were 
calculated using MetaXl version 5.3. The data extraction for both studies was done independently 
by two reviewers. 
 
  
   
iv 
 
Results 
Out of the sixteen patients, three developed infection leaving the overall infection rate to 18.75%. 
Chemotherapy induced gastroenteritis was documented in 68.7% of the cases, chemotherapy 
induced mucositis was documented in 43.7% of the cases. Most of the infections occurred during 
neutropenia (92.3%) and 69.2% of them during febrile neutropenia. 
No gastroenteritis was microbiologically confirmed, all were clinically documented infections. 
Bacterial infections accounted for 12.5% (2/16 cases) one upper respiratory tract infection and one 
urinary tract infection. Whereas viral infections, pneumonia and urinary tract infections were each 
6.25% (1/16 cases respectively). There was no prevalence of bloodstream infection or central line 
associated bloodstream infection for any of the patients. 
As for the meta-analysis, the aggregated results were studied in the 10 included studies. 
Significant heterogeneity was noted among the studies (I2 = 99%; P = 0.0001), the pooled 
prevalence of blood stream infection among 55789 AHSCT patients from the ten studies was 6%, 
95% CI: 0, 33. 
Conclusion  
This study provides original baseline data about the prevalence of HAI among AHSCT in 
NCCCR. These findings will be used for additional evaluation of the influence of infection 
prevention and control measures and therapeutic plans for these patients. They will also 
contribute to the enhancement of the quality of care in NCCCR, mainly in the hematopoietic stem 
cell transplant unit (HSCT) through the proper implementation of the infection control standards 
and proper implementation of antimicrobial stewardship program. 
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CHAPTER 1: INTRODUCTION 
Types of Healthcare Associated Infections 
The HAIs are of two types: 1-The endogenous infections are infections that occur when 
the patient is contaminated by his own germs. The patient's medical situation, i.e. his age 
and pathology, his treatment, the quality of care and the presence of pathogenic germs for 
certain fragile patients, are involved. 2-The exogenous infections that are either infection 
transmitted from one patient to another, or infections caused by the germs of the carer or 
linked to the contamination of the hospital environment. 
The origin (causes) of these infections are a lack in hygiene practices: it has recently been 
shown that the major cause of bacterial transmission is lack of hygiene, mainly lack of 
hand washing (1). Advances in medicine and surgery with, for example, increasingly 
aggressive care and therapeutics, may be a possible source of infection. For the most part, 
the main distinguished HAIs are the infections of superficial or deep surgical wounds 
(Surgical Site Infections or SSI), the urinary tract infections (symptomatic and 
asymptomatic bacteriuria), the primary bacteremia (Bloodstream Infection or BSI) / 
sepsis, the respiratory infections (pneumonia) and catheter infections. 
The most affected services, in descending order, are intensive care units, surgery, and 
medicine. Lower risk services are pediatric and psychiatric services and among the 
bacteria responsible for infections in hospitals, the proportion of multidrug-resistant 
strains is among the highest globally (2) 
Burden of Healthcare Associated Infections  
Healthcare associated infections (HAIs) are recognized as major public health problems 
due to their frequency, cost and severity. The risk of contracting a hospital infection in 
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the U.S is 1 in 25 patients and this figure varies depending on the service in which the 
person is hospitalized for. It can reach higher numbers in a service like intensive care unit 
(3). According to the Center of Disease Control (CDC), HAI Data and Statistics 2011, the 
types of the most prevalent nosocomial infections are pneumonia, gastrointestinal 
infections (GI), urinary tract infections (UTI), primary blood stream infections and 
surgical site infections (SSI)(4). 
Moreover, HAIs lead to prolonged hospital stays. This may lead to 10.7 additional days 
in hospital on average per case of nosocomial infection reaching 16.7% cumulative 
mortality due to infections a year after infection (5). Some patients suffer long-term 
impairment and some others lose their lives. 
The human cost is unacceptable. Other than the physical effect and death, the adverse 
event for the patient is a source of stress and affects the morale and leads to added 
suffering and psychological burden.This was clearly mentioned in one of the CDC 
reports, higher rates of nosocomial infections contributes to increased mortality rates, and 
a negative increase in patient outcomes (4). Since HAI is naturally linked to health-care 
workers’ behavior like substandard hand hygiene practices and sometimes to health-care 
system breaches (e.g. unavailability of the right equipment), this load will definitely lead 
to an intense disappointment and mistrust in the system and health-care professionals (6). 
Each year, the treatment and care to hundreds of millions of patients worldwide is 
complicated by these infections acquired during health care stay. Some patients are then 
in a more serious condition than would have been under normal circumstances. The HAIs 
rates mainly depend on the acuteness of disease, on medical interventions and having 
invasive devices and undergoing procedures, especially ventilator use, central venous 
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catheters (CVCs) and urinary catheters use (7). Many of these infections are resistant to 
at least one antibiotic. Antibiotic resistance generates $ 16.6 billion to $ 26 billion per 
year in additional costs to the healthcare system of United States (8).  
In addition, when speaking about the financial cost, in case of severe sequelae, the 
infection sometimes leads to disability, loss of income or job loss. Not to forget about the 
economic and social cost ending up with increased number of procedures, increased 
antibiotic treatments, increased care prices and as a result the health care systems bears a 
heavier financial burden (9). 
Complications of healthcare associated infections in autologous hematopoietic stem 
cell transplant recipients 
The AHSCT patients are commonly susceptible to infections during the pre and recent 
post-engraftment phase and this infection risk remains up to six to twelve months after 
the transplant. The common types of infections after AHSCT are pneumonia, which is 
one of the frequent complications in the early post-engraftment phase, sometimes with 
invasive aspergillosis or with the reactivation of the cytomegalovirus (CMV). Diarrhea 
can occur as well in the early post engraftment phase: it can be of non-infectious origin or 
infectious such as Clostridium Difficile diarrhea. Bloodstream infections (BSI) are also 
common in the AHSCT patients. They are mainly related to the central venous access or 
caused by mucosal barrier injury (gastrointestinal tract or lungs). Hepatitis B 
seroconversion and development of acute hepatitis especially can occur in patients 
diagnosed with multiple myeloma. Neutropenia and neutropenic fever are also common 
complications during the pre-engraftment period. Mucositis, mucosal inflammation, 
occurring on the digestive tract (oral cavity, oropharynx and esophagus) during 
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myeloablative conditioning regimens is a common complication and it is principally due 
to mucosal injury (10). 
Significance and implication 
The National Center for Cancer Care and research (NCCCR) part of Hamad Medical 
Corporation was inaugurated in 2004.Hematopoietic stem cell transplantation is a 
potentially curative therapeutic modality for many hematologic and non-hematologic 
conditions. As a fruitful outcome of Qatar’s National Cancer Strategy, the hematopoietic 
stem cell transplantation program has been started in the NCCCR in October 2015.  
Since the opening of this new service, no surveillance studies were conducted to estimate 
the prevalence of HAIs in the first year of operation. What is currently done is the routine 
infection prevention and control surveillance and routine reporting of the infections 
encountered without special segregation for hematopoietic stem cell transplant patients. 
The study findings will help in monitoring and tracking future HAIs in AHSCT as well as 
in setting a baseline for future studies in this population. 
To our best of knowledge, there were no meta-analysis conducted to quantify the 
prevalence of one or all of these infections and complications in patients who underwent 
AHSCT. 
Aim  
The aim of the study is to contribute to the improvement of the quality of care in Hamad 
Medical Corporation (HMC) cancer center, mainly in the hematopoietic stem cell 
transplant unit (HSCT) through the proper implementation of the infection control 
standards. 
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Objectives 
• To assess the prevalence of HAIs and infectious complications among the AHSCT 
patients up to discharge and set the baseline for future studies in NCCCR. 
• To identify overall and site specific infection rates and mortality among the AHSCT 
patients up to discharge. 
• To estimate the global prevalence of BSI, one of the most prevalent HAIs among the 
AHSCT and compare that among different populations. 
Research questions  
• What is the overall and site-specific prevalence of healthcare associated infectious 
complications in AHSCT at the new NCCCR transplant unit a year after functioning? 
• What is the global prevalence of blood stream infection, one of the most common 
health care associated infectious complications after an AHSCT? 
• How is this prevalence in the new NCCCR HSCT unit compared with that in other 
populations? 
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CHAPTER 2: LITERATURE REVIEW 
Prevalence of healthcare associated infections worldwide 
Estimates of the extent of the problem are limited by the lack of reliable data. The 
consequences on health care facilities and the communities are unknown in most 
countries. 
No health facility or country or health system can claim to have solved this problem with 
HAI still affecting hundreds of millions of people worldwide and being a major problem 
for patient safety. 
In modern health facilities and developed countries, 5 to 10% of patients acquire one or 
more HAI. “In developing countries, the risk of HAI is 2 to 20 times higher than in 
developed countries; the proportion of patients affected can exceed 25%. In intensive 
care units, the HAI affect approximately 30% of patients, and the associated mortality 
can reach 44%” (6). 
HAI is causing more serious illnesses, extension of the length of hospital stay, long-term 
impairment, unwanted mortality, additional economic burden and high individual 
personal costs for clients. It was demonstrated that the validated and standardized 
prevention strategies can reduce 50% of the HAI. Most preventive measures are simple 
and inexpensive; they can be implemented both in developed countries and in countries 
with limited resources (6). 
The Study on the Efficacy of Nosocomial Infection Control (SENIC) showed that over 
30% of HAI can be avoided with a good infection control program (11). The European 
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Prevalence of Infection in Intensive Care (EPIC) study on the prevalence of HAI in 
intensive care units emphasized on the importance of taking the specific measures for 
infection control and prevention in critically ill patients (12). 
Risk factors of healthcare associated infections 
Many risk factors contribute to HAI such as the use of invasive equipment or catheters, 
and certain patient’s populations such as trauma, burns or immunocompromised patients 
who are more susceptible groups (13). 
In addition to the usual risk factors for community urinary tract infection, the main risk 
factor for nosocomial urinary tract infection is the existence of a urethral catheter. The 
risk of nosocomial urinary infection increases with indwelling catheters. 
Artificial ventilation is the main risk factor for respiratory tract infections and pneumonia 
infection. The intubation probe and the tracheotomy cannula are foreign bodies; they 
necessarily involve an inflammatory process of the laryngeal and / or tracheal mucosa on 
contact with them. 
Infections of the surgical site are caused by the patient’s endogenous skin flora or by 
breaking the aseptic operative technique, or inappropriate preoperative antibiotics 
administration, or the operating room environment, or bacterial, viral, and fungal 
contamination presented by the operative staff (14). 
Intravascular devices are the gateway to infections due to the breakdown of the natural 
skin barrier. The infectious risk increases with the duration of maintenance of the central 
venous catheter and the frequency of manipulations on the infusion line. Intravascular 
devices are the major source; accounting for about third of nosocomial blood stream 
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infections. A remote infectious focus may also be associated with nosocomial bacteremia, 
particularly a urinary, pulmonary and digestive focus. Prolonged neutropenia is also one 
of the main risk factors, so permanent attention should be given to the problem of 
nosocomial infections particularly in high-risk patients. Hospitals should actively 
participate in the fight against infections and this should be part of a continuous quality 
improvement (15)(16). 
Complications of healthcare associated infections 
Septicemia or bloodstream infection caused by central venous catheters represents a 
major category in HAIs. The mortality and morbidity risk of these infections is high 
(50%) and the reduction in their prevalence may be achieved by preventing infections. 
Prevention of sepsis caused by central venous catheters therefore deserves the attention of 
every health care institution and every health professional (17). 
In a national approximation of the death related to HAIs conducted by the Centers for 
Disease Control and Prevention in the US hospitals in 2002 where they used diverse 
approaches along with three data sources, among them the National Nosocomial 
Infections Surveillance (NNIS) system data, the numbers of “estimated death related to 
HAIs were 98,987. Of these, 35,967 were related to pneumonia, 30,665 to bloodstream 
infections, and 13,088 to urinary tract infections, 8205 to surgical site infections, and 
11062 for infections of other sites”. This national approximation deduced that the HAIs 
in hospitals are a noteworthy source of morbidity and mortality in the United States (9). 
But death related to HAI varies according to the place of hospitalization with 30% of the 
HAIs observed in intensive care units accounting for notable and significant morbidity 
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and mortality rates (13). 
Prevalence of healthcare associated infections in immunosuppressed patients  
Any person admitted to a healthcare facility is likely to develop an infection. Those who 
are particularly sensitive are the ones with immune deficiency. Infectious complications 
after hematopoietic stem cell transplants are frequent and potentially severe. 
In hematology, aplasia will be the consequence of the chemotherapy effect on the bone 
marrow and the risk of infection will be high. In fact, the white cell count drops to a 
figure lower than 500 / mm3, with reduction particularly in polymorph nuclear which are 
the main anti-bacterial and anti-fungal agents.Therefore, the high prevalence of HAI is a 
recurrent complication in patients with hematological malignancies, due to the harshness 
of their disease that regularly lead to severe immunosuppression ,due to the 
chemotherapeutic agents, ending up with central line associated blood stream infection as 
one of the most frequent types of infections (18). 
After AHSCT, patients are at remarkable risk of getting one or more HAIs, especially 
during the neutropenia phase of their treatment. Infection occurs mainly because of 
immunosuppression and the most important phase to be considered is the neutropenic 
status post engraftment. In this particular phase, infection prevention and control 
measures are essential (19). Bacterial infections are the most dominant and they cause 
many complications. They mostly cause bloodstream infections, pneumonia and 
gastrointestinal infections (20). 
Among the hematology-oncology patients with neutropenia, the prevalence of central line 
associated bloodstream infection is the highest and there is a high recommendation for 
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the infection rates to be monitored in hematology-oncology wards (21). 
The effect of bloodstream infection is evident throughout the post-hematopoietic stem 
cell transplantation (HSCT) period. Bloodstream infection (BSI) is significantly 
associated with death throughout this post-HSCT period (22). The different risk factors 
associated with HAI were the prolonged neutropenia days and the duration of fever (23). 
Several authors have provided information on these special aspects. Infection is 
responsible for the majority of deaths after allogenic and autologous transplants. Hospital 
associated infections such as bloodstream infections, pneumonias and diarrhea are 
common among these particular patients and account for significant costs and morbidity 
(24).The infectious risks of HSCT and the measures to decrease these complications were 
reviewed by Magauran et al. Of these measures, many are related to healthcare worker’s 
behavior and environmental control. Of course, the challenges will remain for clinicians 
despite the marked advances in the field of HSCT. These measures need to be 
implemented prior to transplant and during the engraftment phases (24). 
The long neutropenic period <1 × 10(9)/L beyond nine days, was found to be the single 
risk factor for bacteremia. Pinana et al. (22) wrote “the identification of such risk factors 
may be helpful to implement prophylactic and therapeutic risk-adapted strategies to 
reduce the prevalence of bacteremia in AHSCT”.  
The evaluation of the profile of bloodstream infections in patients after HSCT was 
described in a polish study that was conducted in patients after HSCT in 5 centers of the 
Polish Pediatric Group for Hematopoietic Stem Cell Transplantation in 2012-2013. The 
study showed that the description of BSI rely on the latent illness and HSCT donor type 
  
   
11 
 
(25).Consideration should also be given to potential viral reactivations in autologous 
HSCT patients (26). 
The intensive use of chemotherapy, development of surgery and radiotherapy techniques 
and mastery of supportive care has led to significant improvement in the survival of 
cancer patients. Nevertheless, the aggressiveness of the treatment and the use of 
increasingly frequent invasive procedures, such as central venous access, expose this 
vulnerable population to infectious complications. These are a major cause of morbidity 
and mortality patients with cancer. These infections prolong hospital stay and increase 
the cost of its management significantly. Therefore, the implementation of strategies to 
fight against these infections is critical. The neoplastic disease and the aggressiveness of 
treatment are responsible for a deep and prolonged immunosuppression, which increases 
the risk of infection in oncology- hematology patients. When  monitoring these 
infections, the factors of intrinsic and extrinsic risk can be analyzed, microbial and 
evolution of bacterial resistance to antibiotics can be studied, progress and identify areas 
of prevention can be monitored (27). 
Surveillance of healthcare associated infections 
This worldwide burden of the HAI stays obscure due to the difficulty assembling solid 
and reliable information. In hospitals, ambulatory and long-term care, HAI gives off an 
impression of being a hidden, crosscutting issues that no organization or nation can claim 
to have illuminated yet. HAI surveillance is needed, it is complicated and necessitates the 
utilization of systematic standards, handiness of diagnostic facilities and competence to 
conduct it and interpret the results. Surveillance frameworks for HAIs do exist in a few 
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high-income nations and yet are nonexistent in most low-and mid-income nations (6). 
In the 1970s, U.S public health officials paid heed to expanding numbers of HAIs and 
their consequences of expanded hospital costs, morbidity, and mortality. Healthcare 
facilities started applying infection control programs; in any case, their effectiveness was 
un-evidenced. In 1974, Haley and others at the CDC (28) composed the SENIC national 
Project to look at whether disease control and surveillance projects could bring down the 
rates of HAIs. This study performed over a 10-year time span (1975 to 1985), inspected 
HAI rates in a sample of United States clinics before and after applying the infection 
control programs. This project demonstrated that the rates of the four common HAIs were 
“reduced by 32%  by applying programs comprising surveillance with feedback of 
infection control rates to hospital staff, enforcement of preventative practices, supervision 
by infection preventionist to collect and analyze surveillance data, and  the involvement 
of a physician or microbiologist with specialized training in infection prevention and 
control” (28). 
This study has affirmed the success of infection control surveillance programs and 
empowered an expansion in their quantities all through healthcare facilities in the United 
States. In the early 1990s, following the experience of the National Nosocomial 
Infections Surveillance System (NNIS) in the United States, several European countries 
began to set up surveillance network. In 1994, a first coordination was financed by the 
European Commission, as part of the creation of the Hospitals in Europe Link for 
Infection Control through Surveillance (HELICS) program. In 1998, a mandate to 
standardize the epidemiological surveillance of communicable diseases was given to the 
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HELICS network. The Institute of Medicine published in 2000 “To Err Is Human: 
Building a Safer Health System” and subsequently drew attention to preventable medical 
errors, including HAIs and patient safety (29).Then in 2003, the Joint Commission issued 
the first-ever National Patient Safety Goals requiring from each accredited hospital to 
show their programs that inscribe the reduction in healthcare associated infections as a 
target vis-a-vis enhancement of the patient safety. They particularly endorsed the 
conformity to the CDC or the World Health Organization’s hand hygiene guidelines and 
the reporting of death related to Healthcare associated infections as an “unanticipated 
event not related to the natural course of the patient's illness” (30). 
The Surgical Site Infection Network was created in Denmark and the septicemia network 
in Belgium is among the first set up. In 2002 and 2003, the HELICS network produced 
standardized protocols for SSI surveillance and nosocomial infections in resuscitation. 
From 2005 to 2008, surveillance continued under the Improving Patient Safety in Europe 
(IPSE) network (31). 
Infection surveillance and control programs began expanding after the report of SENIC 
was out. They started using a standardized surveillance methodology, the infection rates 
were reported through databases such as the National Nosocomial Infection Surveillance 
system that was replaced in 2005 by the National Health Safety Network (NHSN) based 
at the CDC. Elements of this novel system started to be followed worldwide.  
The Council's recommendation of 9 June 2009 encouraged the European Union member 
states to organize periodic prevalence surveys. It confirmed the importance of targeted 
surveillance for certain types of infections, such as SSI. It also underlined the essential 
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role of an early warning system and it recommends using the indicators of organization or 
means proposed by the European CDC. 
Prevalence surveys on SSI have also been the subject of a European protocol in 2010. 
The purpose of these surveys was to sensitize hospitals to the surveillance and prevention 
of healthcare acquired infections, to assess their importance and to describe them, and to 
evaluate national strategies when these surveys are repeated. 
Many developed countries in Europe and Americas are now having proper hospital 
surveillance for infections and they are giving a big attention to infection prevention and 
control programs that can reduce the rates and sometimes eliminate the HAIs. 
In Qatar, the HMC Infection Control program was established in the late eighties and has 
expanded enormously throughout the years to comprise in 2016 a team of 25 persons 
distributed across its eight facilities. The aim of the Infection Prevention and Control 
program (IPAC) in HMC is to protect patients, protect healthcare personnel, and promote 
safety, quality, and value in the healthcare delivery system. The program is 
comprehensively maintained, outlining the structure and function throughout the 
organization. The Infection Control Corporate Committee and the Infection Control 
Team from each HMC facility have the responsibility for monitoring it. 
The multidisciplinary, systematic and coordinated approach was developed to minimize 
the risk of spread of infections between patients, family, health care workers and visitors. 
The IPAC within HMC facilities has a well-defined written plan and takes into account 
the goals, mission statement, and the annual review of surveillance data and risk 
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assessments of each facility’s infection control program. The surveillance system for 
health care associated infection is prioritized based on the high risk and high volume of 
procedures and treatment, which includes device-associated infections such as central 
line associated bloodstream infection, ventilator associated event and catheter associated 
urinary tract infection, procedure associated infection such as SSI including implant 
surgeries and multi-drug resistant organisms. The documents, reports of data analysis and 
recommendations are provided to leadership on a quarterly basis (32). 
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CHAPTER 3: METHODS 
 Two studies were conducted. The first is the NCCCR study to assess the 
prevalence of HAIs, the infectious complications and site specific and overall infection 
rates and mortality among the AHSCT in Qatar. The second is the meta-analysis 
conducted to estimate the global prevalence of BSI, one of the most prevalent HAIs 
among the AHSCT and compare that among different populations including Qatar. 
NCCCR Study  
Descriptive NCCCR study assessing the prevalence of specific hospital associated 
infectious complications post AHSCT and the mortality related. Data was collected from 
the electronic medical records of all AHSCT patients who attended the HSCT unit in the 
NCCCR from October 2015 to October 2016. 
Study population 
The inclusion criteria for the cases were adult patients of 14 years and above, who 
underwent AHSCT in NCCCR between October 2015 and October 2016. Sixteen 
autologous-transplanted patients were identified. 
Ethical consideration 
The study relied on data extraction from electronic medical records and it did not require 
informed consent from the study participants as no contact was made with anyone of 
them. HMC and Qatar University IRB committees gave the ethical approval. For both 
studies, data collection and entry were validated by two qualified practitioners along with 
the researcher for quality assurance purposes and stored confidentially in her office on 
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locked access computers.  
Data collection  
Data collection from the electronic record of each patient and the hospital stay from 
admission to discharge were reviewed up to discharge. Complications related to hospital 
infection were compiled. From the electronic medical records, confirmed infections by 
microbiology laboratory for tests that were previously obtained mainly from blood and 
urine culture results, stool samples and soft tissue swabs where compiled as well. The 
isolates that were confirmed by the microbiology laboratory were assembled into 
bacterial families. The presence of localized infections, with or without microbiologic 
confirmation was used to determine clinically documented infections or 
microbiologically documented infections. Patients who suffered from diarrhea, 
Clostridium Difficile infections were accounted for toxin-producing strains and diarrhea 
without positive stool culture or clinical manifestation of infection was recorded as 
chemotherapy induced diarrhea. All the positive microbiological tests without clinical 
manifestations, like skin-commensals, were not considered. The isolation site was used to 
determine the type of infection and was divided into bloodstream infections (BSI) and 
central line associated bloodstream infections, urinary tract infections (UTI) and catheter 
associated urinary tract infections, gastroenteritis, mucositis, bacterial, fungal or viral 
infection, and pneumonia. All significant pathogens from blood cultures and physician’s 
notes for oral mucositis and diarrhea were considered. The prevalence of infection was 
obtained based on the CDC definition of HAI. If the patient had the same infection twice, 
within a window period of 14 days, it will be considered as same infection. 
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The variables extracted were: age, sex, diagnosis, comorbidity, febrile neutropenia, mean 
duration of neutropenia, infections during neutropenia, antibiotic administration and 
death all during the 30 hospital days. 
Data collection tools 
The tools that were used to collect the data: 
1) Electronic medical records system in NCCCR. 
2) Developed data collection sheet (appendix B), based on NHSN and CDC latest 
criteria (January 2017). 
Main outcome variables  
1) Specific Hospital Associated Infectious complications post AHSCT 
•  Pneumonia 
•  Bloodstream infection (BSI) 
•  Central line associated blood stream infection (CLABSI) 
•  Urinary tract infection (UTI) 
•  Catheter associated urinary tract infection (CAUTI) 
•  Gastrointestinal infection 
•  Mucositis 
2) Mortality related to these Hospital Associated Infectious complications post AHSCT. 
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Statistical analysis 
The basic statistical descriptive methods were performed using STATA software 
version14. The entire healthcare associated infections (HAI) and other variables were 
described using means, proportions and 95% confidence intervals. 
Meta-analysis 
Search methodology 
For the meta-analysis, the synthesis that took place followed a rigorous methodology 
ensuring the impartiality of the synthesis and its reproducibility. The systematic review 
was conducted in conformity to the Meta-Analysis of Observational Studies in 
Epidemiology guidelines. I ran a systematic search in English in PubMed from 1970 
(date of stem cell transplant kick off) to 2016 using search terms as MeSH “Stem cell" 
OR "marrow" OR “cord”, OR “autologous “AND "transplant" AND “BSI” OR 
“bloodstream infection” OR “sepsis” OR “bacteremia “OR “clabsi” OR “complications” 
AND “humans”. 
Inclusion criteria 
Inclusion was restricted to human hematology studies that included autologous 
hematopoietic stem cell transplant, full-text articles written in English and studies 
reporting infections/complications after AHSCT. Studies performed on pediatric 
population and studies that presented data in a non-extractable format (i.e., infection in 
two types of transplants together) were excluded.  
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Data extraction 
For the data extraction, two reviewers (J.D.N and M.A.H.S) separately appraised all 
abstracts for studies that met the eligibility criteria as well as citations by titles. Articles 
with full-text version of all potentially relevant studies were retrieved and separately 
assessed for illegibility. Relevant information from the text, tables, and figures of eligible 
articles were gathered and summarized using an excel spreadsheet. Unanimity was 
attained if there were any dissimilarity among the reviewers. 
The following data were obtained: the characteristics of each study, including the study 
design, the country of origin, and the study period. I also obtained information on the 
patient population including prevalence of BSI in the AHSCT patients’ population. 
Quality assessment 
I used the modified Newcastle-Ottawa Quality Assessment Scale for case-control as well 
as for cohort studies to evaluate the quality of the studies (appendices C and D). The 
scales assessed whether the authors tackled the measures against bias. The quality criteria 
were combined into a score composed of one variate, as shown in table 5 and table 6. The 
Quality score was established on a new scale between zero and one (Qi score); it was 
done by adding the points of each component and dividing it by the highest sum obtained 
by a study within the meta-analysis, the best quality study will have a Qi of one. In the 
Cohort studies, the cohort representativeness had 2 points if it was truly representative 
and 1 point if somewhat representative. The case selection for non-BSI had 1 point if it 
was drawn from the same community as the BSI cases, zero point if drawn from another 
source. Ascertainment of exposure got 2 points if it was taken from a secure record and 1 
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point if it was from interview or self-written report. The demonstration of the BSI not 
present at start had 1 point if it was not present and zero if it was present at the start of the 
study. The assessment of the outcome received 2 points if it was independent/blind, 1 
point if it was taken from a record and zero points if self-reported or no information. The 
comparability got 1 point if the study adjusted for confounders and zero points if not. In 
the Case control studies, the case definitions had 2 points if the validation was 
independent, 1 point if   from records or self-report and zero if no information. The case 
representativeness had 1 point if it was representative and zero if potential selection bias. 
The selection of controls got 2 points if it was taken from the community and 1 point if it 
was from the hospital. The definition of controls had 1 point if BSI was not present at the 
start and zero if no information. The ascertainment of exposure received 2 points if it was 
taken from secure records, 1 point if it was self-reported or no information. The 
comparability got 1 point if the study adjusted for confounders and zero points if not. 
Statistical analysis 
The primary outcome of interest was the prevalence of BSI among AHSCT patients. It 
was pooled using IVhet and QEM (33) (34) and displayed by forest plot. 
Statistical calculations allowing an accurate estimation of the prevalence were calculated 
using MetaXl version 5. Heterogeneity was assessed with Tau–squared statistics. A 
subgroup analysis was done by geographic location (USA versus Europe and India) to 
check if there was a difference in BSI rates and per antibiotic prophylaxis to check 
whether antibiotics had an effect on reducing BSI rate. The funnel and Doi plots were 
examined to assess the possibility of publication bias. 
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CHAPTER 4: RESULTS 
Descriptive National Center for Cancer Care and Research (NCCCR) study  
Characteristics of the patients are presented in Table 1. In the analyzed period of time, 
from October 2015 to October 2016, 16 patients underwent AHSCT. The mean age was 
46.37 (range 31 to 57years), SD 8.30 and majority were males 11(69%). 
Eleven (69%) patients were diagnosed with multiple myeloma, 1(6%) with a refractory 
plasmacytoma, 1(6%) with relapsing diffuse large B-cell lymphoma (DLBCL), 2(13%) 
with refractory Hodgkin lymphoma and 1(6%) with relapsing Mantle cell lymphoma. The 
mean duration of neutropenia was 6.31 days (range 4 to 10 days). Comorbidities as well 
as febrile neutropenia were present in 9 patients (56%). There were 12(75%) patients who 
had infection during neutropenia and during the 30 hospital days, 14(87.5%) patients 
received antibiotics and no death was observed in any of the patients up to discharge. 
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Table 1 Characteristics of AHSCT recipients 
*Comorbidity includes diabetes, hypertension, renal impairment and rheumatic heart disease 
 
The Prevalence and characteristic of infection are presented in Table 2. Infectious 
complications during neutropenia accounted for 92.3% of the patients. Among patients 
with infections, febrile neutropenia accounted for 69.2% (9/16 cases).  
Clinically documented infections were more prevalent (11/16 cases) than the 
microbiology documented ones (2/16 cases). 
 
 
 
 
 
 
                                  Frequency (%) 
Number of patients 16(100) 
Mean age –Years  46.37 
Sex   
  Male 11(69) 
  Female 5(31) 
Diagnosis 
   Multiple myeloma 
   Refractory plasmacytoma 
   DLBCL  
   Refractory Hodgkin lymphoma 
   Mantle cell lymphoma  
 
11(69) 
1(6) 
1(6) 
2(13) 
1(6) 
Comorbidity* 9(56) 
Febrile neutropenia 9(56) 
Mean duration of neutropenia- days 6.31 
Infection during neutropenia 12(75) 
Infection during hospital stay 12(75) 
Antibiotics 14(87.5) 
Death 0(0) 
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Table 2 Characteristics of AHSCT recipients with infectious complications according to 
diagnosis and neutropenia status 
 
*MDI: Microbiologically documented infection    CDI: Clinically documented infection 
The infectious complications encountered in the AHSCT recipients are presented in table 
3a. Out of the sixteen patients, three developed infection leaving the overall infection rate 
to 18.75%. Most of the infections occurred during neutropenia (92.3%) and 69.2% of 
them during febrile neutropenia. There was no gastroenteritis microbiologically 
confirmed, all were clinically documented infections. Bacterial infections accounted for 
12.5% (2/16 cases) one upper respiratory tract infection and one urinary tract infection. 
Whereas viral infections (Cytomegalovirus), pneumonia and urinary tract infections 
accounted each for 6.25% (1/16 cases respectively) of the infections. There was no 
prevalence of bloodstream infection or central line associated bloodstream infection for 
any for the patients. As for the chemotherapy induced complications, gastroenteritis and 
 With infection N 
(%) 
   *MDI N (%) *CDI N 
(%) 
Diagnosis 
   Multiple myeloma 
   Refractory plasmacytoma 
   DLBCL  
   Refractory  
   Mantle cell lymphoma  
 
8(61.5) 
1(7.6) 
1(7.6) 
1(7.6) 
2(15.3) 
 
0(0) 
1(50) 
0(0) 
1(50) 
0(0) 
 
8(72.7) 
0(0) 
1(9.1) 
0(0) 
2(18.2) 
Febrile neutropenia    
    Yes 9(69.2) 1(50) 8(72.7) 
    No 4(30.7) 1(50) 3(27.7) 
Infection during neutropenia    
    Yes 12(92.3) 2(100) 10(91) 
    No 1(7.7) 0(0) 1(9) 
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mucositis had, with respectively 68.7% and 43.75% as shown in table 3b. 
 
Table 3a Infectious complications encountered in the AHSCT recipients 
         No* Percentage 95% CI 
Overall infection            3 18.75 5.3%-48% 
Bacterial Infection 2 12.5 3.5%-36% 
Fungal infection 0 0 0%-19.3% 
Viral Infection 1 6.25 1.1%-28% 
Pneumonia 1 6.25 1.1%-28% 
Bloodstream infection (BSI) 0 0 0%-19.3% 
Central line associated blood stream infection 0 0 0%-19.3% 
Urinary tract infection 1 6.25 1.1%-28% 
Catheter associated urinary tract infection 0 0 0%-19.3% 
 
 
 Table 3b Chemotherapy induced complications in the AHSCT recipients 
 
Meta-analysis  
Yield of search strategy 
The search strategy determined 2588 unique publications, the titles of which were 
screened one by one for inclusion, 2444 were excluded due to outcomes other than BSI 
(irrelevant articles, one prevalence of all types of infections, not only BSI and articles 
with pediatric population). Neither meta-analysis (13, all irrelevant) nor systematic 
         No* Percentage 95% CI 
Gastroenteritis 11 68.7 44.4%-85.8% 
Mucositis 7 43.75 23.1%-66.8% 
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reviews relevant to the search criteria (48, all irrelevant) were found. The abstracts of the 
remaining 144 studies were screened for inclusion of which 108 studies were excluded 
(pediatric populations, type of HSCT was not mentioned and irrelevant reviews). I ended 
up with 36 studies. From these, I excluded three old original articles that were not found 
(with the librarian aid) and five studies where prevalence was given for both types of 
HSCT mixed, not only autologous.(The authors were contacted and only two replied that 
they have no primary data, the study was conducted 20 years ago).Two studies where BSI 
is only given for Vancomycin Resistant Enterococci (VRE), one study where BSI is only 
given for streptococcus Mitis, two irrelevant articles without any BSI prevalence, eight 
irrelevant reviews without any BSI prevalence, five studies where in the analysis they 
included pediatrics were all excluded. Ten final relevant studies remained for the meta- 
analysis (Figure1). 
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                      PRISMA Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 
flowchart of the literature search conducted in January 2017 for the systematic review and meta-
analysis. 
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of HSCT not mentioned)  
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Studies included in 
qualitative synthesis  
(n =36) 
Studies included in quantitative 
synthesis (meta-analysis) 
(n =10) 
 
Excluded: 
• 3 original articles not found 
• 5 studies where prevalence is given for 
not only autologous, allogenic as well. 
• 2 studies where BSI is given only for 
VRE 
• 1 study where BSI is only given for 
Streptococcus Mitis 
• 2 irrelevant articles without BSI 
prevalence 
• 8 irrelevant reviews without BSI 
prevalence 
• 5 studies where in the analysis they 
included pediatrics 
                                 (n=26) 
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Characteristics of the included studies 
The population studied had 55789 patients aged 16 years and above who underwent 
autologous HSCT from the United States, France, Finland, Poland, Germany and India. 
Median age in eight studies ranged from 36 to 56 years with one study reported to include 
patients with age more than 16 years old and the other to have an age range from 18 to 65 
years old. The proportion of female subjects ranged from 22.7 % to 63.6% across all 
studies. Five studies were in the U.S while the other four were in different European 
countries and one in India. Included studies ranged from 1989 to 2008 with duration from 
1 year to 14 years. Seven studies were nested case-control, whilst the others were cohort 
studies. Gagan et.al. had a very large sample size of 53,337 to Yi Kong-Keung et.al. with 
a sample size of only 11 patients. The rate of BSI using CDC definitions, ranged from 
5.2% to 63.6 %. (Table4). The quality scores of the ten studies ranged from 4 to 8 out of 
a maximum of nine (Tables 5 and 6). 
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Table 4 Studies evaluating BSI according to CDC definitions, in AHSCT patients from 1989 to 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
Author (year) Country Study period Study type Sample 
size 
Age Female (%) Rate of BSI 
(%) 
Gagan Kumar et.al (2015) (35) U.S. 2000-2008 Nested case-control 53,337 18->65 43.4 5.2 
Michael J. Satlin (2014) (36) U.S. 2007-2011 Nested case-control 287 56(44-63) Not reported 37.9 
Lalit Kumar (2010) (37) India 1995-2009 Nested case-control 44 35(15-67) 22.7 47.7 
Sari Hamalainen (2009) (38) Finland 1996-2006 Nested case-control 319 55(16-73) 40.7 21 
L. Gil (2007) (39) Poland 1994-2005 Nested case-control 314 36(16-67) 44.2 33.7 
MH Miceli (2006) (40) U.S. 1998-2002 Retrospective 
cohort 
367 56(30-77) 38.6 19.8 
M. Dettenkofer (2005) (41) Germany 2003-2005 Prospective cohort 726 >16 Not reported 18.1 
AA Toor (2001) (42)  U.S. 1996-1998 Retrospective 
cohort 
107 46(14-63) 54.2 28 
Nicolas Ketterer (1998) (43) France 1989-1997 Nested case-control 277 48(15-68) 37.9 20.5 
Y.Kong-Keung (1995) (44) U.S. 1995 Nested case-control 11 46(31-62) 63.6 63.6 
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 Table 5 Newcastle Ottawa Quality Assessment Scale for the cohort studies included in the meta-analysis 
Author, 
publication year 
Cohort  
representativeness 
Case 
selection 
 for non-
exposed 
Ascertainment  
of exposure 
BSI not 
present at 
start 
Assessment 
of outcome 
Analysis 
adjusted  
for 
confounders 
Total 
score 
 (points) 
MH.Miceli et al 
2006 
2 1 1 1 0 1 6/9 
M. Dettenkofer et 
al 2005 
2 1 2 1 1 0 7/9 
AA. Toor et al 
2001 
2 1 2 1 1 1 8/9 
 
 
 
 
 Table 6 Newcastle Ottawa Quality Assessment Scale for the case-control studies included in the meta-analysis 
Author, 
publication year 
Definition  
of cases 
cases 
Representativeness 
Selection 
of controls 
Analysis 
adjusted  
for 
confounders 
Ascertainment  
of exposure 
Definition of  
controls 
Total 
score 
(points) 
Gagan Kumar et.al 
2015 
1 1 1 1 2 0 6/9 
M. Satlin et al 2014 1 1 1 1 1 1 6/9 
L.Kumar et al 2010 0 1 1 0 1 1 4/9 
S.Hamalainen et al 
2009 
1 1 1 1 2 1 7/9 
L. Gil et al 2007 0 1 1 1 1 0 4/9 
N.Ketterer et al 1998 1 1 1 1 2 0 6/9 
Y.Kong-Keung et al 
1995 
1 1 1 1 2 0 6/9 
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Quantitative analysis 
The aggregated results were reviewed in the 10 studies and illustrated in Figure (2). I 
obtained very close results in both IVhet (6%, 95% CI: 0, 33) and QE (10%, 95% CI: 0, 
33). Significant heterogeneity was noted among the studies (I2 = 99%; P = 0.0001). 
Figure 2. Forest plot with IVhet model 
Subgroup analysis 
Across the five studies conducted in America, the estimated prevalence of BSI was 5 % 
(95% CI 0%-36%), which was much lower than the estimated prevalence among 
European and Asian studies 23 % (95% CI 13%-34%). As the 95% CI overlap, no 
significance difference was observed. 
Moreover, I stratified the studies based on the number of patients>200 and <200 and 
found that the estimated BSI prevalence was 6 times higher in studies with number of 
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participant>200. The Prevalence was 36 %, 95% CI 15%-58% and 6 %, 95% CI 0%-32% 
respectively. The stratification per antibiotic prophylaxis administration showed that with 
prophylaxis, the BSI prevalence was lower (Table 7). 
 
 Table 7 Subgroup analysis of the summary estimates  
 
 
 
 
 
Publication bias 
The funnel plot of 10 studies using BSI prevalence as the outcome indicator was showed 
in Figures 3a and 3b. There was a significant asymmetry observed in the Doi and funnel 
plots, and an obvious publication bias (I² 98.9%) was seen. 
  
Figure 3a. Doi plot of all studies 
Bloodstream Infections Studies N Combined effect 
(95% CI) 
I² 
All studies 10 57789   
  Studies≥200 patients 7 55627 36 %( 15%-58%) 77% 
  Studies≤200 patients 3 2162 6 %( 0%-32%) 99% 
Geographic region     
  America 5 54109 5 %( 0%-36%) 99% 
  Europe and Asia 5 3680 23 %( 13%-34%) 93% 
Antibiotic prophylaxis 7 56733 6 %( 0%-37%) 99% 
No antibiotic prophylaxis 3 1056 19 %( 0%-84%) 90% 
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Figure 3b. Funnel plot of all studies 
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CHAPTER 5: DISCUSSION 
 
In this single hospital, retrospective descriptive analysis for the period going from 
October 2015 to October 2016, looking at HAI after autologous hematopoietic stem cell 
transplant, I found that only18.75% of the patients had an infectious complication during 
their admission period. Diarrhea was one of the common complications and it was, most 
probably related to the high-dose chemotherapy regimens they were on (45). 
The rate of microbiologically proven bacterial infections in our patients (12.75%) was 
comparable to that reported by others for autologous hematopoietic stem cell transplant. 
However, some authors have reported higher rates (40). 
It has been well documented from several similar studies that bloodstream infections can 
be of a high prevalence after AHSCT, but such infections were not observed in my study. 
In contrast, I did not have a single case of bloodstream infection or sepsis. The low 
remarked prevalence of bloodstream infection might be attributable to the antimicrobials 
administered during preparation and immediately after AHSCT periods (14 patients 
received antibiotics (87.5%)) or due to the short duration of neutropenia (39). 
Neutropenia duration of more than 9 days is well known as the utmost risk factor for the 
occurrence of fungal infections and it is considered to be the single independent risk 
factor for bloodstream infection in the AHSCT patients (23) (40). I had a mean duration 
of neutropenia of 6.31 days. The prevalence of infections in the NCCCR HSCT unit 
compared with that in other populations, share many similarities with other published 
infection rates in patients post AHSCT. The NCCCR study showed no increase in BSI 
risk following the autologous transplant, it was not at all encountered and there was no 
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death occurrence. As for the meta-analysis, I found an overall prevalence of BSI of 6%. 
Indeed, recipients of hematopoietic stem cell transplants are at a particular risk of 
bloodstream infection a large number of published studies addressed this association. 
Interestingly there was a remarkable distinction seen in the reported prevalence of BSI 
for studies having a large sample size, they had higher prevalence, this might be due to 
the unknown confounders like the difference in infection control measures 
implementation or the different level of care implemented in each of the settings. 
There was as well a difference between the geographical locations; the studies conducted 
in America had an prevalence lower than the ones conducted in Europe and India this 
might be due to their well-established antibiotic stewardship guidelines as it was first 
implemented in the United States hospitals in 2006 by the Society of Healthcare 
Epidemiology of America (SHEA) (47). It was also noted that there was a 13% reduction 
in the prevalence of BSI when antibiotic prophylaxis was administered. 
The main most important study limitation was its small sample size. I only had 16 
patients who underwent the autologous transplantation during the study period. 
Other limitations are the study’s retrospective nature; all the information about the 
infections was procured retrospectively and the potential patients selection biases. 
In this manner, given these restrictions, our data must be cautiously interpreted. The 
small sample size made the estimates of prevalence imprecise and this was demonstrated 
by the wide 95% CI. 
In conclusion, this study provides original baseline data about the prevalence of HAI 
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among AHSCT in NCCCR. These findings will be used for further evaluation of the 
influence of infection prevention and control measures and therapeutic plans, including 
robust antibiotic stewardship well-functioning program for these patients for the purpose 
of contributing to the improvement of the quality of care in NCCCR, especially in the 
hematopoietic stem cell transplant unit (HSCT). In accordance with prior experience and 
study findings, our data is adding confirmation that most of hospital associated infections 
in AHSCT patients are acquired throughout neutropenia (19) (20) (22). Carrying on with 
surveillance and initiation of further studies involving hygiene measures and antibiotic 
use in hematologic stem cell transplantation units, are required to additionally assess the 
risk factors that contribute to severe infection in this category of patients. These findings 
may have implications for the clinical management of stem cell transplant recipients, one 
of them is to correct any deficiency found in medical records during the study, the second 
is with regards to optimizing prophylactic and treatment strategies in AHSCT recipients 
the third is to create a collaborative work to investigate HAIs among AHSCT in GCC 
countries. Evidence based infection control strategies should continue to be applied in the 
transplant unit leading subsequently to less hospital associated infections. 
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APPENDIX A: DEFINITIONS 
Healthcare Associated Infections (HAI): also, called nosocomial infections, are 
infections that patients acquire during receiving treatment for other conditions within a 
healthcare setting. They are defined as those that develop during hospitalization but are 
neither present nor incubating upon the patient’s admission to the hospital; generally, for 
those infections that occur more than 48 to 72 hours after admission and within 10 days 
after hospital discharge (CDC 2004). 
Hematopoietic Stem cell transplant (HSCT): is the intravenous infusion of 
hematopoietic stem and progenitor cells designed to establish marrow and immune 
function in patients with a variety of acquired and inherited malignant and nonmalignant 
disorders. These include hematologic malignancies (e.g., leukemia, lymphoma, and 
myeloma), nonmalignant acquired bone marrow disorders (e.g., aplastic anemia), and 
genetic diseases associated with abnormal hematopoiesis and function (thalassemia, 
sickle cell anemia, and severe combined immunodeficiency). HSCT is also used in the 
support of patients undergoing high-dose chemotherapy for the treatment of certain solid 
tumors for which hematologic toxicity would otherwise limit drug administration (germ 
cell tumors, and neuroblastoma). 
Neutropenia is an abnormally low level of neutrophils. Neutrophils are a common type 
of white blood cell important to fighting off infections — particularly those caused by 
bacteria. For adults, counts of less than 1,500 neutrophils per microliter of blood are 
considered to be neutropenia. 
ANC engraftment is defined as 3 consecutive days with an ANC (absolute neutrophil 
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count) of 0.5 × 109/L or 1 day with a count of 1.0 × 109/L. 
Engraftment: Days 0-30. Is when the body accepts the transplanted bone marrow or stem 
cells and they begin to produce new blood cells and immune system cells. It is a step in a 
successful stem cell transplant. 
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APPENDIX B: DATA COLLECTION SHEET 
 
Data collection sheet -Hematopoetic stem cell transplant case
Surveillance of Healthcare Associated Infections in Adult Recipients of Autologous Hematopoietic Stem-Cell Transplantation (AHSCT) 
at The National Center for Cancer Care and Research Qatar, a year after opening the transplant unit.
Please write inside number and date frames or place a cross in the appropriate box using a black pen 
Abstractor's Initials 
Abstractor's corporation number
Date of admission: ……….mm ………..dd………..yy
Admission type : Elective(1)Urgent(2)
Age : ……….yy
Sex : Male(1) Female(2)
Nationality : Qatari(1) Other(2)
Diagnosis: Multiple myeloma(1) Plasmacytoma(2) Follicular lymphoma(3)
other 4(please write)
Date of HSCT …….mm ………..dd………..yy
Date of discharge: ……….mm ………..dd………..yy
Death yes (1) No(2)
Comorbidity yes (1) No(2)
Comorbidity type Diabetes(1) HTA (2) Neutropenic (3) 
Other(4)
Febrile neutropenia yes (1) No(2)
Duration of neutropenia ……….dd
Date of infection ……..mm ………..dd………..yy
Invasive devices yes (1) No(2)
Type of intravascular device HL(1) PICC(2) other(3)
Type of urinary catheter FC(1) other(2)
Healthcare associated infection yes (1) No(2)
if yes ,Healthcare associated infection type : 
BSI (1)
CLABSI (2)
CAUTI (3)
Pneumonia(4)
Gastroenteritis(5) Type 
Cdifficile(6)
Mucositis(7)
Other(8)
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Infection Non Healthcare associated yes (1) No(2)
if yes ,type : 
BSI (1)
CLABSI (2)
CAUTI (3)
Pneumonia(4)
Gastroenteritis(5) Type 
Cdifficile(6)
Mucositis(7)
Other(8)
Pathogen causing the infection 
Antimicrobial therapy yes (1) No(2)
If yes,choose 
Meropenem (1) Cefuroxime(5) Vancomycin(9)
Azitromycin(2) Co-trimoxazole(6)
Ciprofloxacin(3) Cefepim(7)
Metronidazole(4) Ceftriaxone(8)
Infection during neutropenia yes (1) No(2)
Infection during 30 patient days yes (1) No(2)
Infection during 100 patient days yes (1) No(2)
Infection pre-engraftment period yes (1) No(2)
Infection post-engraftment period yes (1) No(2)
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APPENDIX C: NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE CASE- 
CONTROL STUDIES 
Note: A study can be awarded a maximum of one star for each numbered item within the 
Selection and Exposure categories. A maximum of two stars can be given for Comparability. 
Selection 
1) Is the case definition adequate? 
a) yes, with independent validation ¯ 
b) yes, e.g. record linkage or based on self-reports 
c) no description 
2) Representativeness of the cases 
a) consecutive or obviously representative series of cases ¯ 
b) potential for selection biases or not stated 
3) Selection of Controls 
a) community controls ¯ 
b) hospital controls 
c) no description 
4) Definition of Controls 
a) no history of disease (endpoint) ¯ 
b) no description of source 
Comparability 
1) Comparability of cases and controls on the basis of the design or analysis 
a) study controls for _______________ (Select the most important factor.) ¯ 
b) study controls for any additional factor ¯ (This criterion could be modified to indicate specific 
control for a second important factor.) 
Exposure 
1) Ascertainment of exposure 
a) secure record (e.g. surgical records) ¯ 
b) structured interview where blind to case/control status ¯ 
c) interview not blinded to case/control status 
d) written self-report or medical record only 
e) no description 
2) Same method of ascertainment for cases and controls 
a) yes ¯ 
b) no 
3) Non-Response rate 
a) same rate for both groups ¯ 
b) non-respondents described 
c) rate different and no designation 
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APPENDIX D: NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE 
COHORT STUDIES 
Note: A study can be awarded a maximum of one star for each numbered item within the 
Selection and Outcome categories. A maximum of two stars can be given for Comparability 
Selection 
1) Representativeness of the exposed cohort 
a) truly representative of the average _______________ (describe) in the community ¯ 
b) somewhat representative of the average ______________ in the community ¯ 
c) selected group of users e.g. nurses, volunteers 
d) no description of the derivation of the cohort 
2) Selection of the non-exposed cohort 
a) drawn from the same community as the exposed cohort ¯ 
b) drawn from a different source 
c) no description of the derivation of the non-exposed cohort 
3) Ascertainment of exposure 
a) secure record (e.g. surgical records) ¯ 
b) structured interview ¯ 
c) written self-report 
d) no description 
4) Demonstration that outcome of interest was not present at start of study 
a) yes ¯ 
b) no 
Comparability 
1) Comparability of cohorts on the basis of the design or analysis 
a) study controls for _____________ (select the most important factor) ¯ 
b) study controls for any additional factor ¯ (This criterion could be modified to indicate specific 
control for a second important factor.) 
Outcome 
1) Assessment of outcome 
a) independent blind assessment ¯ 
b) record linkage ¯ 
c) self-report 
d) no description 
2) Was follow-up long enough for outcomes to occur 
a) yes (select an adequate follow up period for outcome of interest) ¯ 
b) no 
3) Adequacy of follow up of cohorts 
a) complete follow up - all subjects accounted for ¯ 
b) subjects lost to follow up unlikely to introduce bias - small number lost - > ____ % (select an 
adequate %) follow up, or description provided of those lost) ¯ 
c) follow up rate < ____% (select an adequate %) and no description of those lost 
d) no statement 
 
